enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Bristol Myers Squibb acquires Karuna Therapeutics for $14 ...

   www.aol.com/news/bristol-myers-squibb-acquires...

   The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna's stock on Thursday. Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a ...

3. Bristol Myers to buy schizophrenia drugmaker Karuna ...

   www.aol.com/news/bristol-myers-buy-schizophrenia...

   (Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older ...

4. Bristol Myers to buy RayzeBio for $4.1 billion in targeted ...

   www.aol.com/news/bristol-myers-buy-rayzebio-4...

   Bristol will pay $62.50 for each share of RayzeBio in cash, representing a premium of 104% to the stock's last close. RayzeBio shares, which had risen 27% since their market debut in September ...

5. Bristol Myers Squibb - Wikipedia

   en.wikipedia.org/wiki/Bristol_Myers_Squibb

   Citing major developments and a market capitalization of US$87 billion and stock appreciation of 61.4%, Bristol-Myers Squibb was ranked as the best drug company of 2013 by Forbes magazine. [ 46 ] In December 2014, the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot ...

6. NBI-1117568 - Wikipedia

   en.wikipedia.org/wiki/NBI-1117568

   With a PANSS improvement of 7.5, NBI-111758 lagged behind xanomeline/trospium (KarXT) (Karuna Therapeutics) with 8.4 and emraclidine (Cerevel Therapeutics) with 12.7, both of which were in clinical trials at the same time. Moreover, the lack of dose-dependency led to disappointment in the stock market. [18]

7. Karuna Therapeutics' Schizophrenia Drug Could Be a ... - AOL

   www.aol.com/karuna-therapeutics-schizophrenia...

   However, in the past year, its stock is down about 11%. Of the 16 analysts who rated Karuna in January, Yahoo Finance reported the opinions are evenly split between buy and strong buy, with a high ...

8. Daphne Zohar - Wikipedia

   en.wikipedia.org/wiki/Daphne_Zohar

   She is the founder and CEO [1] of Seaport Therapeutics, [2] co-founder of Karuna Therapeutics, [3] and Founding CEO of PureTech Health. [4] She sits on the board of BIO [5] and is a co-founder and host of Biotech Hangout. [6] She was named one of the most influential people in Biopharma in 2023. [7] MIT Technology Review TR35 top innovators .

9. Bristol Myers' schizophrenia drug reduces symptoms without ...

   www.aol.com/news/bristol-myers-schizophrenia...

   Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight ...